Mind Medicine (MMQ) Stock Forecast & Price Target

Compare

11 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MMQ Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Mind

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MMQ Stock 12 Month Forecast

Average Price Target

€24.06

▲(199.25%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Mind Medicine in the last 3 months. The average price target is €24.06 with a high forecast of €46.71 and a low forecast of €15.29. The average price target represents a 199.25% change from the last price of €8.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","47":"€47","14.75":"€14.75","25.5":"€25.5","36.25":"€36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.7103989,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.0601018334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.28703964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,14.75,25.5,36.25,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,8.762338376923076,11.924676753846153,15.08701513076923,18.249353507692305,21.411691884615387,24.57403026153846,27.736368638461535,30.898707015384616,34.06104539230769,37.22338376923077,40.385722146153846,43.54806052307692,{"y":46.7103989,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,7.020007833338461,8.440015666676924,9.860023500015386,11.280031333353847,12.700039166692308,14.120047000030771,15.540054833369233,16.960062666707692,18.380070500046156,19.80007833338462,21.22008616672308,22.640094000061545,{"y":24.0601018334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,6.345156895384615,7.090313790769231,7.835470686153846,8.580627581538462,9.325784476923076,10.070941372307692,10.816098267692308,11.561255163076922,12.306412058461538,13.051568953846154,13.79672584923077,14.541882744615384,{"y":15.28703964,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.405,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.935,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.505,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.475,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€46.71

Average Price Target€24.06

Lowest Price Target€15.29

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-GartnerEvercore ISI

Evercore ISI

€19.68

Buy

144.75%

Upside

Reiterated

07/11/25

Evercore ISI Sticks to Its Buy Rating for Mind Medicine (MNMD)

Jay OlsonOppenheimer

Oppenheimer

€29.09

Buy

261.80%

Upside

Initiated

06/02/25

Mind Medicine (MNMD) Initiated with a Buy at Oppenheimer

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

€47.06

Buy

485.26%

Upside

Reiterated

05/21/25

Mind Medicine's Strategic Advancements and Late-Stage Pipeline Progress Justify Buy Rating

Marc GoodmanLeerink Partners

Leerink Partners

€17.11

Buy

112.82%

Upside

Reiterated

05/09/25

Mind Medicine's Promising Pipeline and Robust Financial Health Drive Buy Rating

Rudy LiChardan Capital

Chardan Capital

€17.11

Buy

112.82%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD) and AbCellera Biologics (NASDAQ: ABCL)

Michael OkunewitchMaxim Group

Maxim Group

€15.4

Buy

91.54%

Upside

Reiterated

05/08/25

MindMed's Strategic Positioning and Financial Strength Underpin 'Buy' Rating

Joel BeattyRobert W. Baird

Robert W. Baird

€23.1→€13.69

Buy

70.26%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

€13.69

Buy

70.26%

Upside

Reiterated

03/06/25

Buy Recommendation for Mind Medicine: Promising Phase 3 Trials and Undervalued Market Potential

Brian AbrahamsRBC Capital

RBC Capital

€17.97

Buy

123.46%

Upside

Reiterated

03/06/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), Elevation Oncology (NASDAQ: ELEV) and Xeris Pharmaceuticals (NASDAQ: XERS)

Jason WittesRoth MKM

Roth MKM

€30.8

Buy

283.08%

Upside

Reiterated

07/24/24

Buy Rating on MindMed's MM120: Promising Long-Term Efficacy and Safety in Anxiety Treatment Trials

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-GartnerEvercore ISI

Evercore ISI

€19.68

Buy

144.75%

Upside

Reiterated

07/11/25

Evercore ISI Sticks to Its Buy Rating for Mind Medicine (MNMD)

Jay OlsonOppenheimer

Oppenheimer

€29.09

Buy

261.80%

Upside

Initiated

06/02/25

Mind Medicine (MNMD) Initiated with a Buy at Oppenheimer

Unknown AnalystCantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

€47.06

Buy

485.26%

Upside

Reiterated

05/21/25

Mind Medicine's Strategic Advancements and Late-Stage Pipeline Progress Justify Buy Rating

Marc GoodmanLeerink Partners

Leerink Partners

€17.11

Buy

112.82%

Upside

Reiterated

05/09/25

Mind Medicine's Promising Pipeline and Robust Financial Health Drive Buy Rating

Rudy LiChardan Capital

Chardan Capital

€17.11

Buy

112.82%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD) and AbCellera Biologics (NASDAQ: ABCL)

Michael OkunewitchMaxim Group

Maxim Group

€15.4

Buy

91.54%

Upside

Reiterated

05/08/25

MindMed's Strategic Positioning and Financial Strength Underpin 'Buy' Rating

Joel BeattyRobert W. Baird

Robert W. Baird

€23.1→€13.69

Buy

70.26%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

€13.69

Buy

70.26%

Upside

Reiterated

03/06/25

Buy Recommendation for Mind Medicine: Promising Phase 3 Trials and Undervalued Market Potential

Brian AbrahamsRBC Capital

RBC Capital

€17.97

Buy

123.46%

Upside

Reiterated

03/06/25

Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), Elevation Oncology (NASDAQ: ELEV) and Xeris Pharmaceuticals (NASDAQ: XERS)

Jason WittesRoth MKM

Roth MKM

€30.8

Buy

283.08%

Upside

Reiterated

07/24/24

Buy Rating on MindMed's MM120: Promising Long-Term Efficacy and Safety in Anxiety Treatment Trials

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mind Medicine

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+8.56%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +8.56% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+17.33%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +17.33% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

17/21 ratings generated profit

Average Return

+57.45%

reiterated a buy rating 2 months ago

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +57.45% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+109.59%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +109.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MMQ Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MMQ has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MMQ average Analyst price target in the past 3 months is 24.06.

Each month's total comprises the sum of three months' worth of ratings.

MMQ Financial Forecast

MMQ Earnings Forecast

Next quarter’s earnings estimate for MMQ is -€0.31 with a range of -€0.34 to -€0.25. The previous quarter’s EPS was -€0.23. MMQ beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.43% of the time in the same period. In the last calendar year MMQ has Outperformed its overall industry.

No data currently available

MMQ Sales Forecast

Next quarter’s sales forecast for MMQ is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. MMQ beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.11% of the time in the same period. In the last calendar year MMQ has Preformed in-line its overall industry.

MMQ Stock Forecast FAQ

What is DE:MMQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Mind Medicine Inc.’s 12-month average price target is 24.06.

What is DE:MMQ’s upside potential, based on the analysts’ average price target?

Mind Medicine Inc. has 199.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Mind Medicine Inc. a Buy, Sell or Hold?

Mind Medicine Inc. has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mind Medicine Inc.’s share price target?

The average share price target for Mind Medicine Inc. is 24.06. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €46.71 ,and the lowest forecast is €15.29. The average share price target represents 199.25% Increase from the current price of €8.04.

What do analysts say about Mind Medicine Inc.?

Mind Medicine Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Mind Medicine Inc.?

To buy shares of DE:MMQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mind Medicine (MMQ) Stock Forecast & Price Target

MMQ Analyst Ratings

MMQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mind Medicine

MMQ Analyst Recommendation Trends

MMQ Financial Forecast

MMQ Earnings Forecast

MMQ Sales Forecast

MMQ Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts